Michael Mollerus

Davis Polk advised the joint book-running managers and representatives of the underwriters in an SEC-registered offering by General Dynamics Corporation of $500 million aggregate…

Davis Polk, together with Slaughter and May, is advising Shire plc in connection with a recommended cash and stock offer for Shire’s entire share capital by Takeda Pharmaceutical Company…

Davis Polk advised Goosehead Insurance, Inc. on its $98.095 million initial public offering of 9,809,500 shares of Class A common stock, which includes the full exercise of the underwriters…

Davis Polk is advising Emerson Electric Co. on its $810 million acquisition of the Tools and Test Equipment business of Textron. The transaction, which is expected to close within the next…

Davis Polk is advising Shire plc on the $2.4 billion sale of its Oncology business to Servier S.A.S. The transaction has been approved by the board of directors and is expected to close in…

Davis Polk advised MSCI Inc. in connection with the sale of Financial Engineering Associates, Inc., a wholly owned subsidiary of MSCI, to Allegro Development Corporation. The terms of the…

Davis Polk advised Fogo de Chão, Inc. on the closing of its $560 million acquisition by Rhône Capital. Fogo de Chão is a Brazilian steakhouse operator with locations in Brazil, the United…

Davis Polk advised SS&C Technologies Holdings, Inc. on its $1.4 billion public offering of 30,262,250 shares of common stock, including 3,947,250 shares sold pursuant to an underwriters…

Davis Polk advised Charles River Laboratories International, Inc. in connection with its Rule 144A/Regulation S offering of $500 million aggregate principal amount of 5.500% senior notes…

Davis Polk advised Valeant Pharmaceuticals International, Inc. (“Valeant”) in connection with a refinancing transaction pursuant to which its indirect wholly owned subsidiary, Valeant…